Generation Bio Co. Stock Price, News & Analysis

Generation Bio (NASDAQ: GBIO) has achieved significant progress in its non-viral gene therapy platform, particularly for hemophilia A treatments. Their recent study demonstrated a mean human factor VIII expression of 23% of normal in hemophilia A mice after a single dose of closed-ended DNA (ceDNA) delivered via cell-targeted lipid nanoparticles (ctLNPs). Notably, the therapy was well tolerated across all tested doses in both mice and non-human primates. Generation Bio is on track to select a final candidate for clinical development and begin IND-enabling studies this year.

Generation Bio Co. (Nasdaq: GBIO) announced progress in its non-viral gene therapy programs and third-quarter financial results. The company is on track to advance lead programs into IND-enabling preclinical development in 2021, backed by a strong cash position of $280.4 million as of September 30, 2020. R&D expenses rose to $15.3 million, while G&A expenses increased to $5.7 million, resulting in a net loss of $20.8 million. Key leadership appointments were also announced, including Tracy Zimmermann as Chief Development Officer and Doug Kerr as Chief Medical Officer, to enhance R&D capabilities.

Generation Bio Co. (Nasdaq: GBIO) announced that Phillip Samayoa will present a company overview at the Cell & Gene Meeting on the Mesa, virtually held from Oct. 12-16, 2020. The presentation will be available for on-demand viewing during the conference. Additionally, CEO Geoff McDonough, M.D., will participate in a panel discussion on gene delivery, accessible from Oct. 13. Generation Bio focuses on innovative, non-viral gene therapy for durable treatments of rare and prevalent diseases using proprietary technologies aimed at scalable and effective gene delivery.

Generation Bio Co. (Nasdaq: GBIO), a genetic medicines company, announced that CEO Geoff McDonough will present at the Jefferies 2020 Virtual Gene Therapy/Editing Summit on October 1 at 11:00 a.m. ET. A live webcast of the presentation will be available on the company's investor website and can be replayed for 90 days afterward.

The company's innovative platform focuses on non-viral gene therapy, utilizing proprietary closed-ended DNA and targeted delivery systems to enable durable treatments for various diseases.

Generation Bio, listed as GBIO, reported significant advances in its genetic medicine pipeline and second-quarter financial results. The company successfully completed a $230 million IPO on June 16, 2020, enhancing its robust cash position of $301.1 million as of June 30, 2020. R&D expenses rose to $13.5 million, while G&A expenses increased to $4.3 million. The net loss for the quarter was $17.7 million, up from $15.0 million in 2019. The leadership team was bolstered by the appointment of Dr. Matthew Norkunas as CFO.

Generation Bio (Nasdaq: GBIO), a leader in non-viral gene therapy, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 12, 2020, at 10:20 a.m. ET. The presentation will highlight their innovative platforms, featuring closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP), aimed at providing long-lasting therapies for both rare and prevalent diseases. A live webcast will be accessible on their investor website, with an archive available for 60 days post-event.

Generation Bio Co (Nasdaq: GBIO) announced the appointment of Matthew Norkunas, M.D., MBA, as chief financial officer. Norkunas brings a wealth of experience, having previously served as CFO at SomaLogic and as a senior equity analyst at Marsico Capital Management. His diverse background in healthcare and finance is expected to bolster Generation Bio's strategic initiatives as it seeks to advance its non-viral gene therapy platform. This innovative approach aims to provide sustainable treatments for both rare and prevalent diseases, enhancing the company’s mission to broaden the accessibility of gene therapy.

Generation Bio Co. (Nasdaq: GBIO) has successfully closed its initial public offering, selling 12,105,263 shares at $19.00 each, raising approximately $230 million gross proceeds. This IPO included 1,578,947 shares sold following the underwriters' full exercise of their option for additional shares. Trading under the symbol 'GBIO' began on June 12, 2020. Major underwriters included J.P. Morgan, Jefferies, and Cowen. Generation Bio specializes in innovative genetic medicines, focusing on durable and redosable gene therapies for various diseases.

Generation Bio Co. (Nasdaq: GBIO) has priced its initial public offering (IPO) at $19.00 per share, offering 10,526,316 shares, with gross proceeds expected to be around $200 million. The underwriters hold a 30-day option for an additional 1,578,947 shares. Trading under the symbol 'GBIO' is set to begin on June 12, 2020. J.P. Morgan, Jefferies, and Cowen are the joint bookrunning managers for the offering, which will close on June 16, 2020, pending customary conditions.